LES ULIS, France--(BUSINESS WIRE)--Christian Béchon, Chairman and Chief Executive Officer of LFB since July 2006, was reappointed by a decree from the French President on March 16th, published in the Journal Officiel (Official Journal of the French Republic) on March 18th 2012. Christian Béchon had been put forward for a second mandate as Chairman and Chief Executive Officer of LFB S.A by the new Board of Directors of the Laboratoire français du Fractionnement et des Biotechnologies (LFB S.A), at a meeting held on 15th December 2011 in Paris.
Christian Béchon thus begins a new five-year mandate at the head of LFB S.A., the holding company of the LFB Group, the leading French biopharmaceutical company in the field of plasma-derived medicinal products and 6th player worldwide in the same field.
Christian Béchon presides over a partially renewed Board of Directors (qualified members and State representatives) by a decree published on 25th November 2011. LFB S.A’s Board numbers several new members amongst the qualified members and the State representatives.
LFB board members, qualified members:
Mr René ABATE; Mr Christian BECHON; Mrs Elisabeth HUBERT; Mr Francis MER;
Mr Jean STEPHENNE (new member); Mrs Jean-Marie ZACHARIE (new member).
LFB board members, State representatives:
Mr François AUVIGNE; Mr Christian ESTEVE (new member); Mrs Solenne LEPAGE (new member); Mrs Marie-Christine FAVROT (new member); Mrs Cécile THARAUD (new member); Mr Daniel VASMANT.
The renewal of the employee representatives took place on 31st January 2012, by election.
About LFB: The LFB is a 100% State owned French biopharmaceutical group, which develops, manufactures and markets medicine prescribed for the treatment of serious, and often rare, diseases in major therapeutic fields: immunology, haemostasis and intensive care. Number one in France and 6th player worldwide in the field of plasma-derived medicinal products, the LFB Group, through its subsidiary LFB Biotechnologies, is also one of the leading European companies involved in the development of monoclonal antibodies and new-generation proteins based on biotechnologies. In 2010, 86.5 million euros were thus invested in R&D, with a turnover of 411.6 million euros. The LFB Group has 1835 employees. http://www.lfb.fr/
Sandrine Charrières, + 33 (0)220.127.116.11.80
Corporate Communications Director